Le Lézard
Classified in: Health
Subject: SVY

Coronary Stents Market - Global Forecast to 2026: Technological Advancement in Stent Development to Minimize Restenosis and Improve Patient Compliance


DUBLIN, Sept. 24, 2018 /PRNewswire/ --

The "Global Coronary Stents Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global coronary stents market was valued at US$ 6,216.7 Mn in 2017, and is expected to reach US$ 11,622.5 Mn by 2026, expanding at a CAGR of 7.3% from 2018 to 2026.

In the last 2 decades there has been technological advancement in the manufacturing of stents to counteract complication such as restenosis and stent-in-stent procedure. The only limitation the coronary stents market face is the exorbitant price of drug eluting stents and competition exerted by percutaneous coronary intervention.

Drug eluting stents are currently dominating the coronary stents market on account of key factors such as rising prevalence of coronary artery stenosis, technological advancement in the formulation of biodegradable polymers containing antiproliferative agents to prevent restenosis. Drug eluting stents are completely overshadowing the bare metal stents due to the inherent qualities it possess such as surface smoothness, thinner struts and durable metal alloys. Bioresorbable vascular scaffolds are gaining prominence for the treatment of coronary artery diseases due to key factors such as ability to restore the normal vessel shape and function, eliminate vessel irritation and inflammation and excellent patient compliance.

In the present scenario North America dominates the regional segment for coronary stents market. As per the statistics presented by Center for Disease Control and Prevention (CDC) annually 370,000 U.S. citizens die due to coronary artery disease. The American Africans are at a higher risk for cardiovascular disease on account of their unhealthy lifestyle, tobacco smoking and rise in obesity. In Europe, the market growth is determined by the presence of key players such as Abbott Laboratories, Inc. and Medtronic, Plc. pioneering in manufacturing of coronary stents. Asia Pacific is set to register significant growth during the forecast period owing to the rising prevalence of cardiovascular ailment, rise in per capita income and growth in medical tourism.

Key Market Movements:

Key Topics Covered:

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Coronary Stents Market Portraiture
2.2. Global Coronary Stents Market, by Product, 2017 (US$ Mn)
2.3. Global Coronary Stents Market, by Geography, 2017 (US$ Mn)

Chapter 3. Coronary Stents Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Coronary Stents Market, by Key Players, 2017

Chapter 4. Global Coronary Stents Market, by Product
4.1. Overview
4.2. Drug Eluting Stent
4.3. Bare Metal Stent
4.4. Bioresorbable Vascular Scaffolds

Chapter 5. Global Coronary Stents Market, by Geography

Chapter 6. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/gsfmn5/coronary_stents?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 20:31
Fitness International, LLC opened a new Club Studio location in Kingwood, Texas. The new 40,000 square foot club features five innovative boutique fitness studios that were carefully curated to create a unique experience, along with recovery services...

at 19:35
Mirum Pharmaceuticals, Inc. today announced that on May 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 38,600 shares of common stock and 19,300...

at 19:00
Evolus, Inc. , a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759...

at 18:36
Inhibrx, Inc. ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. ("SpinCo") to holders of shares of...

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...



News published on and distributed by: